SK279180B6 - Použitie rapamycínu alebo jeho kombinácie s inzulí - Google Patents

Použitie rapamycínu alebo jeho kombinácie s inzulí Download PDF

Info

Publication number
SK279180B6
SK279180B6 SK972-92A SK97292A SK279180B6 SK 279180 B6 SK279180 B6 SK 279180B6 SK 97292 A SK97292 A SK 97292A SK 279180 B6 SK279180 B6 SK 279180B6
Authority
SK
Slovakia
Prior art keywords
iddm
rapamycin
insulin
mice
onset
Prior art date
Application number
SK972-92A
Other languages
English (en)
Slovak (sk)
Other versions
SK97292A3 (en
Inventor
William L. Baeder
Surendra N. Sehgal
Laurel M. Adams
Thomas J. Caggiano
Original Assignee
American Home Products Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/792,105 external-priority patent/US5321009A/en
Application filed by American Home Products Corporation filed Critical American Home Products Corporation
Publication of SK97292A3 publication Critical patent/SK97292A3/sk
Publication of SK279180B6 publication Critical patent/SK279180B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Compounds Of Unknown Constitution (AREA)
SK972-92A 1991-04-03 1992-04-01 Použitie rapamycínu alebo jeho kombinácie s inzulí SK279180B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67970691A 1991-04-03 1991-04-03
US07/792,105 US5321009A (en) 1991-04-03 1991-11-14 Method of treating diabetes

Publications (2)

Publication Number Publication Date
SK97292A3 SK97292A3 (en) 1994-11-09
SK279180B6 true SK279180B6 (sk) 1998-07-08

Family

ID=27102296

Family Applications (1)

Application Number Title Priority Date Filing Date
SK972-92A SK279180B6 (sk) 1991-04-03 1992-04-01 Použitie rapamycínu alebo jeho kombinácie s inzulí

Country Status (19)

Country Link
EP (1) EP0507555B1 (da)
JP (1) JP2535119B2 (da)
AT (1) ATE139120T1 (da)
AU (1) AU652037B2 (da)
CA (1) CA2064678A1 (da)
CZ (1) CZ282733B6 (da)
DE (1) DE69211406T2 (da)
DK (1) DK0507555T3 (da)
ES (1) ES2089395T3 (da)
GR (1) GR3020316T3 (da)
HK (1) HK108797A (da)
HU (1) HUT60626A (da)
IE (1) IE74884B1 (da)
IL (1) IL101353A0 (da)
MX (1) MX9201513A (da)
NO (1) NO921279L (da)
NZ (1) NZ242190A (da)
SG (1) SG43075A1 (da)
SK (1) SK279180B6 (da)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5378696A (en) * 1990-09-19 1995-01-03 American Home Products Corporation Rapamycin esters
US5177203A (en) * 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
US5256790A (en) * 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
CA2106034A1 (en) * 1992-09-24 1994-03-25 Ralph J. Russo 21-norrapamycin
US5489680A (en) * 1992-10-13 1996-02-06 American Home Products Corporation Carbamates of rapamycin
US5480988A (en) * 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5434260A (en) * 1992-10-13 1995-07-18 American Home Products Corporation Carbamates of rapamycin
US5480989A (en) * 1992-10-13 1996-01-02 American Home Products Corporation Carbamates of rapamycin
US5302584A (en) * 1992-10-13 1994-04-12 American Home Products Corporation Carbamates of rapamycin
US5349060A (en) * 1993-01-07 1994-09-20 American Home Products Corporation Rapamycin 31-ester with N,N-dimethylglycine derivatives useful as immunosuppressive agents
US5252579A (en) * 1993-02-16 1993-10-12 American Home Products Corporation Macrocyclic immunomodulators
ES2176245T3 (es) 1993-04-23 2002-12-01 Wyeth Corp Anticuerpos de ramapicinas de ciclo abierto.
US7279561B1 (en) 1993-04-23 2007-10-09 Wyeth Anti-rapamycin monoclonal antibodies
US5504091A (en) * 1993-04-23 1996-04-02 American Home Products Corporation Biotin esters of rapamycin
US5387680A (en) * 1993-08-10 1995-02-07 American Home Products Corporation C-22 ring stabilized rapamycin derivatives
US5373014A (en) * 1993-10-08 1994-12-13 American Home Products Corporation Rapamycin oximes
US5378836A (en) * 1993-10-08 1995-01-03 American Home Products Corporation Rapamycin oximes and hydrazones
US5391730A (en) * 1993-10-08 1995-02-21 American Home Products Corporation Phosphorylcarbamates of rapamycin and oxime derivatives thereof
US5385910A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Gem-distributed esters of rapamycin
US5385909A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Heterocyclic esters of rapamycin
US5385908A (en) * 1993-11-22 1995-01-31 American Home Products Corporation Hindered esters of rapamycin
US5389639A (en) * 1993-12-29 1995-02-14 American Home Products Company Amino alkanoic esters of rapamycin
US5525610A (en) * 1994-03-31 1996-06-11 American Home Products Corporation 42-Epi-rapamycin and pharmaceutical compositions thereof
US5362718A (en) * 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US5496831A (en) * 1994-05-13 1996-03-05 The General Hospital Corporation Inhibition of insulin-induced adiposis
US5463048A (en) * 1994-06-14 1995-10-31 American Home Products Corporation Rapamycin amidino carbamates
US5491231A (en) * 1994-11-28 1996-02-13 American Home Products Corporation Hindered N-oxide esters of rapamycin
US5563145A (en) * 1994-12-07 1996-10-08 American Home Products Corporation Rapamycin 42-oximes and hydroxylamines
US5561138A (en) * 1994-12-13 1996-10-01 American Home Products Corporation Method of treating anemia
US5496832A (en) * 1995-03-09 1996-03-05 American Home Products Corporation Method of treating cardiac inflammatory disease
BE1009856A5 (fr) 1995-07-14 1997-10-07 Sandoz Sa Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
TW427904B (en) * 1995-12-07 2001-04-01 American Home Prod Neuroprotective agents
US5780462A (en) * 1995-12-27 1998-07-14 American Home Products Corporation Water soluble rapamycin esters
US5922730A (en) * 1996-09-09 1999-07-13 American Home Products Corporation Alkylated rapamycin derivatives
US6015809A (en) * 1998-08-17 2000-01-18 American Home Products Corporation Photocyclized rapamycin
MXPA03002278A (es) * 2000-09-14 2004-12-03 Beth Israel Hospital Modulacion de respuestas de la celula t mediadas por il-2 e il-15.
DE60329724D1 (de) 2002-06-07 2009-11-26 Waratah Pharmaceuticals Inc Methoden und Kompositionen um Diabetes zu behandeln

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5100899A (en) * 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5023263A (en) * 1990-08-09 1991-06-11 American Home Products Corporation 42-oxorapamycin

Also Published As

Publication number Publication date
JPH0597688A (ja) 1993-04-20
NO921279D0 (no) 1992-04-02
CZ97292A3 (en) 1993-09-15
SG43075A1 (en) 1997-10-17
NZ242190A (en) 1997-06-24
HU9201113D0 (en) 1992-06-29
IE74884B1 (en) 1997-08-13
ATE139120T1 (de) 1996-06-15
CZ282733B6 (cs) 1997-09-17
IE921055A1 (en) 1992-10-07
EP0507555B1 (en) 1996-06-12
HK108797A (en) 1997-08-22
MX9201513A (es) 1993-04-01
EP0507555A1 (en) 1992-10-07
AU652037B2 (en) 1994-08-11
SK97292A3 (en) 1994-11-09
DK0507555T3 (da) 1996-07-01
CA2064678A1 (en) 1992-10-04
IL101353A0 (en) 1992-11-15
ES2089395T3 (es) 1996-10-01
HUT60626A (en) 1992-10-28
DE69211406D1 (de) 1996-07-18
NO921279L (no) 1992-10-05
GR3020316T3 (en) 1996-09-30
DE69211406T2 (de) 1996-11-28
AU1395792A (en) 1992-10-08
JP2535119B2 (ja) 1996-09-18

Similar Documents

Publication Publication Date Title
SK279180B6 (sk) Použitie rapamycínu alebo jeho kombinácie s inzulí
US5321009A (en) Method of treating diabetes
Kane et al. Loss of functional KATP channels in pancreatic β–cells causes persistent hyperinsulinemic hypoglycemia of infancy
Ricordi et al. In vivo effect of FK506 on human pancreatic islets
Nussenblatt et al. Cyclosporine: immunology, pharmacology and therapeutic uses
Fox Androgen treatment prevents diabetes in nonobese diabetic mice.
Gale, Theory and practice of nicotinamide trials in pre-type 1 diabetes
Lytle et al. Ontogeny of amphetamine anorexia and insulin hyperphagia in the rat.
EP2046341B1 (en) Compositions and methods for treating diabetes and neuropsychological dysfunction
Trimble et al. Importance of cholinergic innervation of the pancreas for glucose tolerance in the rat
Gale Nicotinamide: potential for the prevention of type 1 diabetes?
Hellman et al. The cytoplasmic Ca2+ response to glucose as an indicator of impairment of the pancreatic β‐cell function
US5665387A (en) Methods and compositions for primary and secondary prevention of autoimmune diabetes
Kenmochi et al. Protection of mouse islet isografts from nonspecific inflammatory damage by recipient treatment with nicotinamide and 15-deoxyspergualin
Chen et al. Fatty acid inhibition of glucose-stimulated insulin secretion is enhanced in pancreatic islets from insulin-resistant rats
Seemayer et al. Spontaneous diabetes mellitus syndrome in the rat. III. Pancreatic alterations in aglycosuric and untreated diabetic BB Wistar-derived rats
Chlouverakis Insulin resistance of parabiotic obese-hyperglycemic mice (obob)
Corkill The influence of toxaemia on carbohydrate metabolism
WILLIAMS et al. Oral antidiabetic therapy
Schober et al. HLA-DR antigens in insulin-dependent diabetes.
Lahmann et al. DEND Syndrome: Developmental Delay, Epilepsy, and Neonatal Diabetes, a Potassium Channelopathy
Johnson et al. Preliminary clinical evaluation of glybenclamide in treatment of diabetes mellitus
Rubin et al. Mivacurium: A novel, short-acting, nondepolarizing muscle relaxant
Johnsen Endogenous insulin fluctuations during glucose-induced paralysis in patients with familial periodic hypokalemia
Chouhan et al. A COMPREHENSIVE REVIEW OF TYPE-3 DIABETES MELLITUS AND ALZHEIMER'S DISEASE